Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Our purpose was to assess sustained delivery and enhanced efficacy of pirfenidone-loaded nanoparticles after intratracheal instillation.Poly(lactide-co-glycolide) nanoparticles containing pirfenidone (NPs) were prepared and characterized. Biodistribution of NPs and solution was assessed using LC-MS after intratracheal administration in C57Bl/6 mice at 3 and 24 h and 1 week post-administration. Efficacy was tested in C57Bl/6 mice in a bleomycin-induced pulmonary fibrosis model. Mice received 10 μg pirfenidone intratracheally in solution or NPs, once a week, for 3 weeks after bleomycin administration. Drug effects were monitored on day 28. Lung hydroxyproline content, total number of cells, and numbers of macrophages, lymphocytes, and neutrophils in bronchoalveolar lavage (BAL) were assessed. Numbers of macrophages, lymphocytes, and neutrophils were assessed in the lung as well.NPs sustained significantly higher levels of pirfenidone in the lungs and BAL at 24 h and 1 week, compared to the solution group. Pirfenidone solution and NPs significantly reduced hydroxyproline levels by 57 and 81%, respectively, compared to bleomycin alone. At the end of 4 weeks, BAL cellularity was reduced by 25.4% and 56% with solution and NP treatment, respectively. The numbers of lymphocytes and neutrophils in the BAL were also reduced by 58.9 and 82.4% for solution and 74.5% and 89.7% for NPs, respectively. The number of inflammatory macrophages in the lung was reduced by 62.8% and the number of neutrophils was reduced by 59.1% in the NP group and by 37.7% and 44.5%, respectively, in the solution group, compared to bleomycin alone.In conclusion, nanoparticles sustain lung pirfenidone delivery and enhance its anti-fibrotic efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“IPF is a life threatening disease, with approximately 90 000 new cases being diagnosed every year and a median survival rate of 3 years after diagnosis in the United States (US) [2].”
BackgroundHigh-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964 · cited 1×
“A number of other drugs have been evaluated in clinical trials, including interferon-γ [6], warfarin [7], pirfenidone [8], etanercept [9], imatinib [10], bosentan [11, 12], ambrisentan [13], N-acetyl cysteine [14], anti-TGF-β antibody (GC-1008; [13]), TGFβR1 inhibitorSB-525334 [15], αvβ6 antibody [16], P144—a peptide…”
BackgroundBUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454 · cited 1×
“Pirfenidone exhibited similar effects in a bleomycin induced animal model at oral doses of 30–100 mg kg−1 d [48].”
BackgroundPartial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370 · cited 1×
“A number of other drugs have been evaluated in clinical trials, including interferon-γ [6], warfarin [7], pirfenidone [8], etanercept [9], imatinib [10], bosentan [11, 12], ambrisentan [13], N-acetyl cysteine [14], anti-TGF-β antibody (GC-1008; [13]), TGFβR1 inhibitorSB-525334 [15], αvβ6 antibody [16], P144—a peptide…”
Background
Cited by
Nanoparticle-Mediated Pulmonary Drug Delivery: A Review
Paranjpe, M., & Müller-Goymann, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045852 · Cited by 454
Jenkins, R. G., Moore, B. B., Chambers, R. C., Eickelberg, O., Königshoff, M., Kolb, M., Laurent, G. J., Nanthakumar, C. B., Olman, M. A., Pardo, A., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0096st · Cited by 435
Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease
Ruwanpura, S. M., Thomas, B. J., & Bardin, P. G. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0328tr · Cited by 317
Khoo, J. K., Montgomery, A. B., Otto, K. L., Surber, M., Faggian, J., Lickliter, J. D., & Glaspole, I. (2020) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2018.1507 · Cited by 40
Pardeshi, S., Patil, P., Rajput, R., Mujumdar, A., & Naik, J. (2021) · Drying Technology · doi:10.1080/07373937.2020.1833213 · Cited by 37
“excessive fibrosis within the lung parenchyma, characterized by interstitial pneumonia.([7,8]) The drugs avail-”
Background
Metadata
- Authors
- Trivedi, R., Redente, E. F., Thakur, A., Riches, D. W. H., & Kompella, U. B.
- Venue
- Nanotechnology
- Publisher
- IOP Publishing
- Published
- 2012-11-27
- Volume
- 23
- Issue
- 50
- Pages
- 505101
- ISSN
- 0957-4484 (ISSN-L)
- 1361-6528
- OpenAlex
- W2077669802
- Cited by
- 97
- References
- 9
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. https://app.cochat.ai/papers/10.1088/0957-4484/23/50/505101
- The paper
- Trivedi, R., Redente, E. F., Thakur, A., Riches, D. W. H., & Kompella, U. B. (2012). Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. https://doi.org/10.1088/0957-4484/23/50/505101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.